Limitations on Grant. 1. If the Licensed Territory as described on Exhibit B consists of multiple markets and the Licensee's rights under this License Agreement are terminated with respect to one or more of such markets in accordance with the provisions of this License Agreement, Exhibit B to this License Agreement and specifically the term "Licensed Territory" shall thereafter be deemed to apply only to the remaining market(s) as to which Licensee's rights under this License Agreement continue. In addition, the Licensed Territory may be modified, in accordance with the provisions of Section VI.D., in the event that Licensor determines that Potential Customer Confusion exists.
2. Notwithstanding Licensee's exclusive right to utilize the Marks to promote the Primary Services, Additional Services and Additional Products in the Licensed Territory, other persons possessing a license to use the Marks may promote the Primary Services, Additional Products and Additional Services provided by such parties outside of the Licensed Territory in media receiving distribution within or accessible by persons located in the Licensed Territory, such as regional magazines or newspapers, regional television and radio and World Wide Web pages.
3. Subject to the provisions of Sections III.H. and III.I. of this License Agreement, Licensor may terminate Licensee's right to use the Marks to designate or promote certain Core Products, Additional Products and Additional Services.
Limitations on Grant. Backs; Transfer Expenses For purposes of clarity, irrespective of anything to the contrary in this Agreement:
a) All transfers and licenses from Roche to FMI or other obligations of Roche under Section 17.3 are solely with respect to Product(s).
b) In connection with clinical trials, Roche may have collected human samples and related clinical information for additional limited research and development programs (“Samples”). Legal and contractual restrictions may apply to such Samples, in particular as Samples may qualify as personal identifiable information. FMI acknowledges and accepts that notwithstanding anything herein, Roche shall not be obliged to transfer any such Samples to FMI.
c) Nothing in this Agreement shall be construed as granting FMI any license under the intellectual property of Roche or its Affiliates in existence as of the Effective Date.
d) Except with respect to termination by FMI for Roche’s breach pursuant to Section 17.2.2, FMI shall promptly reimburse Roche for all reasonable out-of-pocket costs and expenses (including FTE charges based on Roche’s standard FTE rates) incurred by or on behalf of Roche for transfer of documents and materials as requested by FMI under this Article 17; however transfer activities corresponding to the return of material remains, data, reports, records, documents, Regulatory Filings and Regulatory Approvals originally provided by FMI to Roche (“FMI-Originated Transfer Activities”) shall be at no expense to FMI. If FMI desires Roche Transfer Activities other than FMI-Originated Transfer Activities, FMI shall make a payment to Roche of […***…] (“Minimum Transfer Payment”). The Minimum Transfer Payment shall be non-refundable, but shall be fully creditable against FMI’s reimbursement for the Roche Transfer Activities. Roche shall be under no obligation to provide Roche Transfer Activities (beyond the FMI-Originated Transfer Activities) prior to receipt of the Minimum Transfer Payment.
Limitations on Grant. (a) The grant of rights in Section 2.03 is specifically subject to all of the following:
Limitations on Grant. (1) You shall not alter, delete or in any way destroy the labels with regard to the copyrights, trademarks and other marks in the service products.
(2) You agree not to change the initial settings of the products of this service with the purpose of adding any function, and not to restore, decompile, disassemble, lock, and not to try to find, adapt, modify, transform, convert or alter any font file or data source code, including, take any action sufficient to affect or damage benefits of Arphic.
(3) You agree not to change the initial designs of the products of this service in any way, and not to use the products of this service as the source of materials to develop new and different fonts.
(4) Except as expressly specified in this license agreement, you shall not reproduce, sell, lease, sublicense, exchange, lend, display to the public or spread Arphic fonts (including but not limited to CD, DVD or other storage media, font drivers, font data, etc.), or take any action sufficient to affect the benefits of Arphic.
(5) Whether gratuitous or not, you shall not sell, spread, lease, lend, sublicense the font outline files of this service or take any action sufficient to affect the benefits of Arphic through ASP or by other similar ways such as uploading the fonts on the Internet (e.g., on-line business card designs or on-line printing services and so on).
Limitations on Grant. Backs; Transfer Expenses For purposes of clarity, irrespective of anything to the contrary in this Agreement:
a) All transfers and licenses from Roche to Eleven or other obligations of Roche under Section 18.3 are solely with respect to Returnable Product(s) that are not Combination Product(s). Such transfers, licenses and obligations do not extend to
(i) other therapeutically active ingredients or therapeutically active products, even if physically mixed, combined or packaged together with a Returnable Product, or
(ii) with respect to Pre-Commercialized Returnable Products, delivery technologies that are proprietary to Roche (through ownership or license) (with the proviso that if Eleven would be unable to use any alternative delivery technology to commercialize such Pre-Commercialized Returnable Product, Roche will in good faith consider making such delivery technologies available to Eleven), even if a Returnable Product is intended (according to the investigation plan, proposed labeling or actual labeling, as applicable) for use with such other therapeutically active ingredients, therapeutically active products, or delivery technologies.
b) In connection with research studies, clinical trials or other activities associated with the development and commercialization of Returnable Products, Roche or other members of the Roche Group may have collected human samples and patient information that may contain personal identifiable information (“Samples and PI Information”). Legal and contractual restrictions may apply to such Samples and PI Information. Eleven acknowledges and accepts that, where Roche in good faith has reasonable concerns that Applicable Law or insufficient patient consent would prohibit the transfer of such Samples and PI Information or subject Roche to liability because of such transfer and subsequent use by Eleven, then Roche shall not be obliged to transfer such Samples and PI Information to Eleven.
c) Nothing in this Agreement shall be construed as granting Eleven any license under the Excluded Roche Patent Rights.
d) If Eleven issues a Continuation Election Notice, then Eleven shall reimburse Roche for all reasonable out-of-pocket costs and expenses (including FTE charges) incurred by or on behalf of Roche for transfer activities from Roche to Eleven under Section 18.3.2 (including costs associated with locating, assembling and populating information into the data room) (“Roche Transfer Activities”) within thirty (30) days after receipt...
Limitations on Grant. Grantee agrees to be bound by all of the terms, provisions, conditions and limitations of the Plan and this Agreement.
Limitations on Grant. The Licensed Mark may not be used by Licensee in connection with any producx xx xxxvice except as expressly set forth in this Amendment.
Limitations on Grant. The Licensed Marks and the Transition Logos may not be used by Licensee in connection with any product or service except as expressly set forth in this Agreement.
Limitations on Grant. 1.2.1 The license granted by this License is a non-exclusive license and nothing contained herein shall be deemed to grant to Licensee any exclusive rights to use the Licensed Marks.
1.2.2 Licensee acknowledges and agrees that the management and operation of the Licensee's Business is separate, distinct and independent from the management and operation of the Business.
1.2.3 The Licensed Marks shall only be used by Licensee in Nevada (the "Territory").
1.2.4 Licensee understands that Licensor has the exclusive right to ownership, use and goodwill associated with the Licensed Marks. Except as provided herein Licensee agrees not to use the Licensed Marks or any variation of such name or word in connection with the Licensee's Business.
Limitations on Grant. NAIT acknowledges that the grant of a Sublease hereunder is a quitclaim grant, made without covenants, representations or warranties in respect of Tishomingo's (i) title in the Segment, or (ii) right to use or make available the Segment to others for the purposes contemplated herein. NAIT further acknowledges (a) that the Segment may be subject to (1) the State of Mississippi's or Tishomingo's determination of its needs for orderly and efficient rail operations,
